MX2020012478A - Metodos y composiciones para el tratamiento de la hipertension pulmonar. - Google Patents
Metodos y composiciones para el tratamiento de la hipertension pulmonar.Info
- Publication number
- MX2020012478A MX2020012478A MX2020012478A MX2020012478A MX2020012478A MX 2020012478 A MX2020012478 A MX 2020012478A MX 2020012478 A MX2020012478 A MX 2020012478A MX 2020012478 A MX2020012478 A MX 2020012478A MX 2020012478 A MX2020012478 A MX 2020012478A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- pulmonary hypertension
- treating pulmonary
- rapamycin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- 229960002930 sirolimus Drugs 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona métodos para tratar la hipertensión pulmonar (por ejemplo, una forma grave de hipertensión arterial pulmonar, por ejemplo, una hipertensión arterial pulmonar de clase funcional III o IV de la OMS) en un individuo, que comprenden administrar al individuo una cantidad eficaz de una composición que comprende nanopartículas que comprenden un inhibidor de mTOR (por ejemplo, rapamicina o un derivado de la misma, por ejemplo, rapamicina) y una proteína transportadora (por ejemplo, una albúmina).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675110P | 2018-05-22 | 2018-05-22 | |
| US201962810290P | 2019-02-25 | 2019-02-25 | |
| US201962820838P | 2019-03-19 | 2019-03-19 | |
| US201962820842P | 2019-03-19 | 2019-03-19 | |
| PCT/US2019/033372 WO2019226685A1 (en) | 2018-05-22 | 2019-05-21 | Methods and compositions for treating pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012478A true MX2020012478A (es) | 2021-03-09 |
Family
ID=68615837
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012478A MX2020012478A (es) | 2018-05-22 | 2019-05-21 | Metodos y composiciones para el tratamiento de la hipertension pulmonar. |
| MX2024010373A MX2024010373A (es) | 2018-05-22 | 2020-11-20 | Metodos y composiciones para el tratamiento de la hipertension pulmonar. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010373A MX2024010373A (es) | 2018-05-22 | 2020-11-20 | Metodos y composiciones para el tratamiento de la hipertension pulmonar. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210085621A1 (es) |
| EP (1) | EP3810091A4 (es) |
| JP (1) | JP7561628B2 (es) |
| KR (1) | KR20210024471A (es) |
| CN (1) | CN112423737A (es) |
| BR (1) | BR112020023431A2 (es) |
| CA (1) | CA3100905A1 (es) |
| IL (1) | IL278814A (es) |
| MX (2) | MX2020012478A (es) |
| SG (1) | SG11202011462SA (es) |
| TW (1) | TW202015659A (es) |
| WO (1) | WO2019226685A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| CA3094453A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| CA3133988A1 (en) * | 2019-03-19 | 2020-09-24 | Abraxis Bioscience, Llc | Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases |
| BR112022007710A2 (pt) | 2019-10-28 | 2022-07-12 | Abraxis Bioscience Llc | Composições farmacêuticas de albumina e rapamicina |
| KR20220120823A (ko) | 2021-02-24 | 2022-08-31 | 주식회사 만도 | 랙구동형 동력 보조 조향장치 |
| CN114732789B (zh) * | 2022-05-05 | 2023-08-22 | 中国药科大学 | 一种用于治疗肺动脉高压的复方长效递药系统及其制备 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| ES2685436T3 (es) | 2002-12-09 | 2018-10-09 | Abraxis Bioscience, Llc | Composiciones y procedimientos para administración de agentes farmacológicos |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| EP3345632A1 (en) | 2005-02-18 | 2018-07-11 | Abraxis BioScience, LLC | Drugs with improved hydrophobicity for incorporation in medical devices |
| EP1928435B8 (en) | 2005-08-31 | 2019-03-20 | Abraxis BioScience, LLC | Compositions of poorly water soluble drugs with increased stability and methods for preparation thereof |
| MX380318B (es) | 2007-03-07 | 2025-03-12 | Abraxis Bioscience Llc | Nanoparticula que comprende rapamicina y albumina como agente anticancer. |
| EP2146707A2 (en) | 2007-05-03 | 2010-01-27 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| CA2963085C (en) * | 2014-10-07 | 2023-02-21 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| KR20240090657A (ko) * | 2015-06-29 | 2024-06-21 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 mTOR 억제제 조합 요법을 사용하여 고형 종양을 치료하는 방법 |
| EA036790B1 (ru) * | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| KR20240144442A (ko) | 2015-06-29 | 2024-10-02 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물에 대한 바이오마커 |
| CN107921050A (zh) * | 2015-06-29 | 2018-04-17 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法 |
| CN110022876A (zh) * | 2016-09-28 | 2019-07-16 | 阿布拉科斯生物科学有限公司 | 治疗线粒体和代谢病症的方法 |
-
2019
- 2019-05-21 EP EP19807397.5A patent/EP3810091A4/en active Pending
- 2019-05-21 MX MX2020012478A patent/MX2020012478A/es unknown
- 2019-05-21 CN CN201980048031.5A patent/CN112423737A/zh active Pending
- 2019-05-21 JP JP2020565354A patent/JP7561628B2/ja active Active
- 2019-05-21 BR BR112020023431-1A patent/BR112020023431A2/pt unknown
- 2019-05-21 CA CA3100905A patent/CA3100905A1/en active Pending
- 2019-05-21 KR KR1020207036401A patent/KR20210024471A/ko not_active Ceased
- 2019-05-21 SG SG11202011462SA patent/SG11202011462SA/en unknown
- 2019-05-21 TW TW108117571A patent/TW202015659A/zh unknown
- 2019-05-21 WO PCT/US2019/033372 patent/WO2019226685A1/en unknown
-
2020
- 2020-11-18 IL IL278814A patent/IL278814A/en unknown
- 2020-11-19 US US16/953,167 patent/US20210085621A1/en active Pending
- 2020-11-20 MX MX2024010373A patent/MX2024010373A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL278814A (en) | 2021-01-31 |
| MX2024010373A (es) | 2024-09-02 |
| US20210085621A1 (en) | 2021-03-25 |
| WO2019226685A1 (en) | 2019-11-28 |
| JP7561628B2 (ja) | 2024-10-04 |
| JP2021526138A (ja) | 2021-09-30 |
| CN112423737A (zh) | 2021-02-26 |
| CA3100905A1 (en) | 2019-11-28 |
| TW202015659A (zh) | 2020-05-01 |
| BR112020023431A2 (pt) | 2021-02-23 |
| SG11202011462SA (en) | 2020-12-30 |
| EP3810091A1 (en) | 2021-04-28 |
| EP3810091A4 (en) | 2022-03-02 |
| KR20210024471A (ko) | 2021-03-05 |
| AU2019274516A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010373A (es) | Metodos y composiciones para el tratamiento de la hipertension pulmonar. | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| EA201990820A1 (ru) | Способы лечения митохондриальных и метаболических нарушений | |
| MX2019002564A (es) | Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas. | |
| EP3326630A3 (en) | Methods and compositions for treating pulmonary hypertension | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
| EA200802135A1 (ru) | Фармацевтические композиции антагонистического антитела к cd40 | |
| EA200802390A1 (ru) | Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
| MX358617B (es) | Formulaciones de inhibidores de dpp iv. | |
| SMT201300096B (it) | Inibitori di prolil idrossilasi | |
| EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
| MX2013004298A (es) | Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa. | |
| EA200801996A1 (ru) | 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов | |
| EA201000329A1 (ru) | Циклические депсипептиды | |
| EA201000814A1 (ru) | 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств | |
| EA200700601A1 (ru) | Производные фениламинопиримидина как ингибиторы bcr-abl | |
| EA200702030A1 (ru) | Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз |